title: Grappling with metastatic risk: bringing molecular imaging of Met expression toward clinical use.
abstract: The availability of a test to assess the likelihood that a given tumor will invade or metastasize would be a useful development in clinical oncology. We propose that multimodality imaging of tumor expression of Met could serve as a prototype for metastatic risk stratification (MRS). Met, a receptor protein tyrosine kinase, is expressed by most solid tumors, and aberrant expression of Met is associated with poor clinical prognosis. We summarize the current status and predict the future direction of research in four areas of molecular imaging and cancer therapy that exploit Met.
authors.affiliation: Van Andel Research Institute, 333 Bostwick Avenue N.E., Grand Rapids, Michigan 49503, USA.
authors.forename: Rick
authors.initials: R
authors.lastname: Hay
authors.forename: Brian
authors.initials: B
authors.lastname: Cao
authors.forename: Ilan
authors.initials: I
authors.lastname: Tsarfaty
authors.forename: Galia
authors.initials: G
authors.lastname: Tsarfaty
authors.forename: James
authors.initials: J
authors.lastname: Resau
authors.forename: George
authors.initials: G
authors.lastname: Vande Woude
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D009362:Neoplasm Metastasis / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis* / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D019859:Proto-Oncogene Proteins c-met